Literature DB >> 26830059

Cytotoxic activity against human neuroblastoma and melanoma cells mediated by IgM antibodies derived from peripheral blood of healthy donors.

Satish Kumar Devarapu1, Srinivas Mamidi2, Frank Plöger3, Othmar Dill4, Ola Blixt5, Michael Kirschfink2, Reinhard Schwartz-Albiez1.   

Abstract

A small percentage of healthy donors identified in the Western population carry antibodies in their peripheral blood which convey cytotoxic activity against certain human melanoma and neuroblastoma cell lines. We measured the cytotoxic activity of sera and plasmas from healthy donors on the human neuroblastoma cell line Kelly and various melanoma cell lines. Antibodies of IgM isotype, presumably belonging to the class of naturally occurring antibodies, exerted cytotoxic activity in a complement-dependent fashion. Apart from complement-dependent tumor cell lysis, we observed C3 opsonization in all tumor cell lines upon treatment with cytotoxic plasmas. Cell lines tested primarily expressed membrane complement regulatory proteins (mCRP) CD46, CD55 and CD59 to various extents. Blocking of mCRPs by monoclonal antibodies enhanced cell lysis and opsonization, though some melanoma cells remained resistant to complement attack. Epitopes recognized by cytotoxic antibodies were represented by gangliosides such as GD2 and GD3, as evidenced by cellular sialidase pretreatment and enhanced expression of distinct gangliosides. It remains to be clarified why only a small fraction of healthy persons carry these antitumor cytotoxic antibodies.
© 2016 UICC.

Entities:  

Keywords:  antitumor cytotoxic natural antibodies; gangliosides; human plasma; melanoma; membrane complement receptor proteins; neuroblastoma

Mesh:

Substances:

Year:  2016        PMID: 26830059     DOI: 10.1002/ijc.30025

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Association of Blood Group Antigen CD59 with Disease.

Authors:  Christof Weinstock
Journal:  Transfus Med Hemother       Date:  2022-01-13       Impact factor: 3.747

2.  Effect of membrane-bound complement regulatory proteins on tumor cell sensitivity to complement-dependent cytolysis triggered by heterologous expression of the α-gal xenoantigen.

Authors:  Yu Wang; Juan Liao; Ya-Jun Yang; Zhu Wang; Feng Qin; Sheng-Ming Zhu; Hong Zheng; Yan-Ping Wang
Journal:  Oncol Lett       Date:  2018-04-12       Impact factor: 2.967

Review 3.  Complement as a Biological Tool to Control Tumor Growth.

Authors:  Paolo Macor; Sara Capolla; Francesco Tedesco
Journal:  Front Immunol       Date:  2018-09-25       Impact factor: 7.561

Review 4.  The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy.

Authors:  Anne Geller; Jun Yan
Journal:  Front Immunol       Date:  2019-05-21       Impact factor: 7.561

5.  Diagnostic Profiling of the Human Public IgM Repertoire With Scalable Mimotope Libraries.

Authors:  Anastas Pashov; Velizar Shivarov; Maya Hadzhieva; Victor Kostov; Dilyan Ferdinandov; Karen-Marie Heintz; Shina Pashova; Milena Todorova; Tchavdar Vassilev; Thomas Kieber-Emmons; Leonardo A Meza-Zepeda; Eivind Hovig
Journal:  Front Immunol       Date:  2019-12-03       Impact factor: 7.561

Review 6.  Oncolytic viruses as immunotherapy: progress and remaining challenges.

Authors:  Laure Aurelian
Journal:  Onco Targets Ther       Date:  2016-05-04       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.